InvestSMART

Paradigm Biopharmaceuticals Limited (ASX: PAR) - Announcements

- Current share price for PAR : $0.200

ASX company news and announcements for Paradigm Biopharmaceuticals Limited (PAR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Paradigm Biopharmaceuticals Limited (PAR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Paradigm Biopharmaceuticals Limited (PAR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Paradigm Biopharmaceuticals Limited (PAR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$120 FDA Grants Paradigm Fast Track Designation For OA 12 Apr 2022 11:38AM $1.205 $0.200 fallen by 83.40%
$120 UK ethics and regulatory approval for Phase 3 study 17 Mar 2022 9:20AM $1.210 $0.200 fallen by 83.47%
$120 Change in substantial holding 9 Mar 2022 4:14PM $1.040 $0.200 fallen by 80.77%
$120 Change of Director's Interest Notice 9 Mar 2022 4:13PM $1.040 $0.200 fallen by 80.77%
$120 Clarification of recent analyst report on Patent Protection 9 Mar 2022 10:54AM $1.015 $0.200 fallen by 80.30%
$120 S&P DJI Announces March 2022 Quarterly Rebalance 4 Mar 2022 5:02PM $1.105 $0.200 fallen by 81.90%
$120 Amended Appendix 4D 24 Feb 2022 12:03PM $1.235 $0.200 fallen by 83.81%
$120 Paradigm 1HY22 Key Activity Highlights 24 Feb 2022 10:15AM $1.255 $0.200 fallen by 84.06%
$120 Half Yearly Report and Accounts 24 Feb 2022 9:47AM $1.265 $0.200 fallen by 84.19%
$120 PPS a new adjunct therapy treatment for patients with MPS VI 11 Feb 2022 10:04AM $1.460 $0.200 fallen by 86.30%
$120 Change of Director's Interest Notice 1 Feb 2022 4:11PM $1.500 $0.200 fallen by 86.67%
$120 Cleansing Notice 1 Feb 2022 4:09PM $1.505 $0.200 fallen by 86.71%
$120 Notification regarding unquoted securities - PAR 1 Feb 2022 4:07PM $1.505 $0.200 fallen by 86.71%
$120 Quarterly Update and Appendix 4C - quarterly 31 Jan 2022 3:15PM $1.460 $0.200 fallen by 86.30%
$120 Results of Meeting 25 Jan 2022 3:35PM $1.415 $0.200 fallen by 85.87%
$120 Paradigm AGM Presentation 25 Jan 2022 9:31AM $1.515 $0.200 fallen by 86.80%
$120 PARADIGM TREATS FIRST SUBJECTS IN PHASE 3 TRIAL OF ZILOSUL 13 Jan 2022 8:29AM $1.790 $0.200 fallen by 88.83%
$120 Paradigm to present at the J.P Morgan Healthcare Conference 12 Jan 2022 4:34PM $1.790 $0.200 fallen by 88.83%
$120 Notice of Annual General Meeting/Proxy Form 24 Dec 2021 8:23AM $1.920 $0.200 fallen by 89.58%
$120 PAR REPORTS POSTIVE TOPLINE RESULTS IN HEART FAILURE MODEL 16 Dec 2021 12:29PM $1.890 $0.200 fallen by 89.42%
$120 Paradigm Presentation for Investor Webinar 2 Dec 2021 10:03AM $2.050 $0.200 fallen by 90.24%
$120 Paradigm Investor Webinar 30 Nov 2021 9:36AM $2.140 $0.200 fallen by 90.65%
$120 Application for quotation of securities - PAR 24 Nov 2021 4:30PM $2.290 $0.200 fallen by 91.27%
$120 Preliminary Results from Phase 2 MPS I Study 23 Nov 2021 8:37AM $2.190 $0.200 fallen by 90.87%
$120 Paradigm CEO Paul Rennie to transition to Non-Exec Chairman 22 Nov 2021 8:46AM $2.150 $0.200 fallen by 90.70%

326 - 350 of 721 results

Page 14 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.